<DOC>
	<DOCNO>NCT00928707</DOCNO>
	<brief_summary>This multicentre , randomize , open-label , phase II study test GIVINOSTAT ( ITF2357 ) combination hydroxyurea population patient JAK2V617F positive Polycythemia Vera non-responders maximum tolerate dose hydroxyurea monotherapy least 3 month . Recruited patient randomly assign one follow treatment group : - group A : 50 mg o.d . oral GIVINOSTAT ( ITF2357 ) combination maximum tolerate dose hydroxyurea monotherapy already use admission study ; - group B : 50 mg b.i.d . oral GIVINOSTAT ( ITF2357 ) combination maximum tolerate dose hydroxyurea monotherapy already use admission study . The two group balance number Centre order provide valuable information treatment regimen . In group assigned dos shall remain stable week 12 , primary endpoint assess , unless specific tolerability issue arise impose dose reduction . After primary endpoint assessment week 12 , one follow treatment schedule choose case case basis achieve clinical response continue 12 week : - Partial Complete Response week 12 : - group A : continue 50 mg o.d . ; - group B : continue 50 mg b.i.d . ; - No Response week 12 : - group A : increase 50 mg b.i.d . ; - group B : increase 50 mg t.i.d.. At time study course , toxicity observe , GIVINOSTAT ( ITF2357 ) treatment discontinue recovery restart reduce dose level . The drug definitively withdrawn case reappearance toxicity even reduce daily dose . Overall , treatment last maximum 24 cumulative week drug administration . The study recruit subject gender establish diagnosis JAK2V617F positive Polycythemia Vera accord revise WHO criterion , need cytoreductive therapy , non-responders maximum tolerate dose hydroxyurea monotherapy least 3 month .</brief_summary>
	<brief_title>Phase II Study GIVINOSTAT ( ITF2357 ) Combination With Hydroxyurea Polycythemia Vera</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Givinostat hydrochloride</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Written Informed Consent . Age â‰¥18 year . Confirmed diagnosis Polycythemia Vera accord revise WHO criteria . JAK2V617F positivity . Nonresponse maximum tolerate dose hydroxyurea monotherapy least 3 month . ECOG performance status &lt; 3 . Use effective mean contraception woman childbearing potential men partner childbearing potential . Willingness capability comply requirement study . Active bacterial mycotic infection require antimicrobial treatment . Pregnancy lactation . A marked baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m , accord Bazett 's correction formula ) . Use concomitant medication prolong QT/QTc interval . Clinically significant cardiovascular disease include : Uncontrolled hypertension , myocardial infarction , unstable angin , within 6 month study start ; ; New York Heart Association ( NYHA ) Grade II great congestive heart failure ; History cardiac arrhythmia require medication ( irrespective severity ) ; A history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) . Positive blood test HIV . Active HBV and/or HCV infection . Platelets count &lt; 100x109/L within 14 day enrolment . Absolute neutrophil count &lt; 1.2x109/L within 14 day enrolment . Serum creatinine &gt; 2xULN . Total serum bilirubin &gt; 1.5xULN . Serum AST/ALT &gt; 3xULN . History disease , metabolic dysfunction , physical examination finding , clinical laboratory finding give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . Interferon alpha within 14 day enrolment . Anagrelide within 7 day enrolment . Any investigational drug within 28 day enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>GIVINOSTAT</keyword>
	<keyword>ITF2357</keyword>
</DOC>